Serial proton magnetic resonance spectroscopic imaging, contrast- enhanced magnetic resonance imaging and quantitative lesion volumetry in multiple sclerosis

Annals of Neurology

Volumn 43, Issue 1, 1998, Pages 56-71

  Narayana, Ponnada A ^a   Doyle, Timothy J ^a   Lai, Dejian ^b   Wolinsky, Jerry S ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; GADOLINIUM; LIPID; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DEMYELINATION; DISEASE MARKER; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; VOLUMETRY;

ADULT; ASPARTIC ACID; BRAIN; CHOLINE; FEMALE; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; LIPID METABOLISM; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 0031891884     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430112     Document Type: Article

References (60)

1. Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992;31:333-336
2. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996;6:259-274
3. Offenbacher H, Fezekas F, Schmidt R, et al. Assessment of MRI criteria for a diagnosis of MS. Neurology 1993;43:905-909
4. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329:1764-1769
5. Khoury SJ, Guttmann CRG, Oray EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994;44:2120-2124
6. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44: 635-641
7. Stone LA, Smith ME, Albert PS, et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology 1995;45:1122-1126
8. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain-barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990;113:1477-1489
9. Grossman RI, Braffman BH, Brorson, JR, et al. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 1988;169:117-122
10. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766
11. Grossman RI, Gonzales-Scarano F, Atlas SM, et al. Multiple sclerosis: gadolinium-enhancement of MR imaging. Radiology 1986;161:721-725
12. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990;40:1764-1769
13. Larsson HBW, Christiansen P, Jensen M, et al. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis. Magn Reson Med 1991;22:23-31
14. Mathews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology 1991;41:1251-1256
15. Arnold DL, Mathews PM, Francis GS, et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992;31:235-241
16. Bruhn H, Frahm J, Merboldt KD, et al. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol 1992;32:140-150
17. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58
18. Arnold DL, Ries GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76-82
19. Kimura H, Grossman RI, Lankinski RE, Gonzalez-Scarano F. Proton MR spectroscopy and magnetization transfer ratio in multiple sclerosis: correlative findings of active versus irreversible plaque disease. Am J Neuroradiol 1996;17:1539-1547
20. Landtblom AM, Sjöqvist L, Söderfeldt B, et al. Proton MR spectroscopy and imaging in acute and chronic multiple sclerosis - ringlike appearances in acute plaques. Acta Radiol 1996; 37:278-287
21. Arnold DL, Mathews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990;14:154-159
22. Narayana PA, Wolinsky JS, Jackson EF, McCarthy M. Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques. J Magn Reson Imaging 1992;2:263-270
23. Miller DH, Austin SJ, Connelly A, et al. Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet 1991;X:337:58-59 (Letter)
24. Wolinsky JS, Narayana PA, Doyle TJ, Lindsey JW. Pathological mechanisms in CNS demyelination: as gleaned by serial magnetic resonance imaging of multiple sclerosis. In: Abramsky O, ed. Frontiers in multiple sclerosis: clinical research and therapy. London: Martin Dumitz, 1997:87-95
25. Brenner RE, Munro PMG, Williams SCR, et al. The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio. Magn Reson Med 1993;29:737-745
26. 1H spectroscopy. J Biol Chem 1992;14:9905-9910
27. Hwang JH, Graham GD, Behar KL, et al. Short echo time proton magnetic resonance spectroscopic imaging of macromolecule and metabolite signal intensities in the human brain. Magn Reson Med 1996;35:633-639
28. Ford CC, Ceckler TL, Karp J, Herndon RM. Magnetic resonance imaging of experimental demyelinating lesions. Magn Reson Med 1990;14:461-481
29. Rodriguez M, Scheithauer B. Ultrastructure of multiple sclerosis. Ultrastruct Pathol 1994;18:3-13
30. Roser W, Hagberg G, Mader I, et al. Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter. Magn Reson Med 1995;33: 811-817
31. UBC/MRI Study Group. The IFNB Multiple Sclerosis Study Group. Interferon 1β is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind placebo-controlled trial. Neurology 1991;45:1277-1285
32. Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13
33. Filippi M, Horsfield MA, Barkhof F, et al. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995;118:1601-1612
34. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-76
35. Mathews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996; 119:715-722
36. Jackson EF, Doyle TJ, Wolinsky JS, Narayana PA. Short TE hydrogen-1 spectroscopic MR imaging of normal human brain: reproducibiliry studies. J Magn Reson Imaging 1994;4:545-551
37. Perona P, Malik J. Scale-space and edge' detection using anisotropic diffusion. IEEE Trans Pattern Artificial Machine Intell 1990;12:629-639
38. Jackson EF, Narayana PA, Falconer JC. Reproducibility of non-parametric feature map segmentation for determination of normal human intracranial volumes with MR imaging data. J Magn Reson Imaging 1994;5:692-700
39. Narayana PA, Borthakur A. Effect of radio frequency inhomogeneity correction on the reproducibility of intra-cranial volumes using MR image data. Magn Reson Med 1995;33:396-400
40. Cline HE, Lorensen WE, Kikinis R, Jolesz F. Three-dimensional segmentation of MR images of the head using probability and connectivity. J Comput Assist Tomogr 1990; 14:1037-1045
41. Cline HE, Lorensen WE, Souza SP, et al. 3D surface rendered MR images of the brain and its vasculature. J Comput Assist Tomogr 1991;15:344-351
42. Doyle TJ, Pathak R, Wolinsky JS, Narayana PA. Automated proton spectroscopic image processing. J Magn Reson [B] 1995;106:58-63
43. Bedell BJ, Narayana PA, Johnston DA. Three-dimensional MR image registration of the human brain. Magn Reson Med 1996; 35:384-390
44. Henriksen O. In vivo quantitation of metabolite concentrations in the brain by means of proton MRS. NMR Biomed 1995;8: 139-148
45. Birken DL, Oldendorf WH. N-Acetyl-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989;13:23-31
46. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981-989
47. Fenstermacher MJ, Narayana PA. Serial proton resonance spectroscopy of ischemic brain injury in humans. Invest Radiol 1990;25:1034-1039
48. De Stefano N, Mathews M, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721-727
49. Nesbit GM, Forbes GS, Scheithauer BW, et al. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991;180: 467-474
50. Raine CS, Wu E. Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol 1993;52:199-204
51. Prineas JW, Barnard RO, Revesz T, et al. Multiple sclerosis: pathology of recurrent lesions. Brain 1993;116:681-693
52. Lassman H, Suchanek G, Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 1994;36(Suppl):S42-S46
53. Bedell BJ, Narayana PA, Wolinsky JS. Dual approach for minimizing false lesion classifications on magnetic resonance images. Magn Reson Med 1997;37:94-102
54. Johnson RT, Griffin DE, Hirsch RL, et al. Measles encephalomyelitis-clinical and immunologic studies. N Engl J Med 1984;310:137-141
55. Major EO, Amemiya K, Tornatore CS, et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992;5:49-73
56. Gendelman HE, Pezeshkpour GH, Pressman NJ, et al. A quantitative analysis of myelin-associated glycoprotein and myelin basic protein loss in different demyelinating diseases. Ann Neurol 1985;18:324-328
57. Rodriguez M, Scheithauer BW, Forbes G, Kelly PJ. Oligodendrocyte injury in an early event in lesions of multiple sclerosis. Mayo Clin Proc 1993;68:627-636
58. Bruck W, Schmied M, Suchanek G, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994;35: 65-73
59. Prineas JW. The neuropathology of multiple sclerosis. In: Vinken PJ, Bruyn GW, Klawans HI., eds. Handbook of clinical neurology, vol 47: demyelinating diseases. Amsterdam: Elsevier Science, 1985:213-257
60. Chang L, Ernst T, Tornatore C, et al. Metabolic abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997;48:836-845